Literature DB >> 36104436

Introducing a depression-like syndrome for translational neuropsychiatry: a plea for taxonomical validity and improved comparability between humans and mice.

Mathias V Schmidt1, Jan M Deussing2, Iven-Alex von Mücke-Heim3,4,5, Lidia Urbina-Treviño3, Joeri Bordes5,6, Clemens Ries3,5.   

Abstract

Depressive disorders are the most burdensome psychiatric disorders worldwide. Although huge efforts have been made to advance treatment, outcomes remain unsatisfactory. Many factors contribute to this gridlock including suboptimal animal models. Especially limited study comparability and replicability due to imprecise terminology concerning depressive-like states are major problems. To overcome these issues, new approaches are needed. Here, we introduce a taxonomical concept for modelling depression in laboratory mice, which we call depression-like syndrome (DLS). It hinges on growing evidence suggesting that mice possess advanced socioemotional abilities and can display non-random symptom patterns indicative of an evolutionary conserved disorder-like phenotype. The DLS approach uses a combined heuristic method based on clinical depression criteria and the Research Domain Criteria to provide a biobehavioural reference syndrome for preclinical rodent models of depression. The DLS criteria are based on available, species-specific evidence and are as follows: (I) minimum duration of phenotype, (II) significant sociofunctional impairment, (III) core biological features, (IV) necessary depressive-like symptoms. To assess DLS presence and severity, we have designed an algorithm to ensure statistical and biological relevance of findings. The algorithm uses a minimum combined threshold for statistical significance and effect size (p value ≤ 0.05 plus moderate effect size) for each DLS criterion. Taken together, the DLS is a novel, biologically founded, and species-specific minimum threshold approach. Its long-term objective is to gradually develop into an inter-model validation standard and microframework to improve phenotyping methodology in translational research.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36104436     DOI: 10.1038/s41380-022-01762-w

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


  133 in total

Review 1.  Global trends in the prevalence and incidence of depression:a systematic review and meta-analysis.

Authors:  Darío Moreno-Agostino; Yu-Tzu Wu; Christina Daskalopoulou; M Tasdik Hasan; Martijn Huisman; Matthew Prina
Journal:  J Affect Disord       Date:  2020-12-09       Impact factor: 4.839

2.  Treatment outcomes for depression: challenges and opportunities.

Authors:  Pim Cuijpers; Argyris Stringaris; Miranda Wolpert
Journal:  Lancet Psychiatry       Date:  2020-02-17       Impact factor: 27.083

3.  Advances in depression research: second special issue, 2020, with highlights on biological mechanisms, clinical features, co-morbidity, genetics, imaging, and treatment.

Authors:  Julio Licinio; Ma-Li Wong
Journal:  Mol Psychiatry       Date:  2020-07       Impact factor: 15.992

Review 4.  Prevalence and clinical course of depression: a review.

Authors:  Derek Richards
Journal:  Clin Psychol Rev       Date:  2011-07-23

5.  The long-term course of depressive disorders in the Lundby Study.

Authors:  Cecilia Mattisson; Mats Bogren; Vibeke Horstmann; Povl Munk-Jörgensen; Per Nettelbladt
Journal:  Psychol Med       Date:  2007-02-19       Impact factor: 7.723

6.  Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials.

Authors:  Marta M Maslej; Toshiaki A Furukawa; Andrea Cipriani; Paul W Andrews; Marcos Sanches; Anneka Tomlinson; Constantin Volkmann; Robert A McCutcheon; Oliver Howes; Xin Guo; Benoit H Mulsant
Journal:  JAMA Psychiatry       Date:  2021-05-01       Impact factor: 21.596

Review 7.  Relevance of Rodent Models of Depression in Clinical Practice: Can We Overcome the Obstacles in Translational Neuropsychiatry?

Authors:  Johan Söderlund; Maria Lindskog
Journal:  Int J Neuropsychopharmacol       Date:  2018-07-01       Impact factor: 5.176

Review 8.  Prognosis and improved outcomes in major depression: a review.

Authors:  Christoph Kraus; Bashkim Kadriu; Rupert Lanzenberger; Carlos A Zarate; Siegfried Kasper
Journal:  Transl Psychiatry       Date:  2019-04-03       Impact factor: 6.222

9.  Analysis of depressive episodes, their recurrence and pharmacologic treatment in primary care patients: A retrospective descriptive study.

Authors:  Shysset Nuggerud-Galeas; Loreto Sáez-Benito Suescun; Nuria Berenguer Torrijo; Ana Sáez-Benito Suescun; Alejandra Aguilar-Latorre; Rosa Magallón Botaya; Bárbara Oliván Blázquez
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.240

10.  The excess costs of depression: a systematic review and meta-analysis.

Authors:  H König; H-H König; A Konnopka
Journal:  Epidemiol Psychiatr Sci       Date:  2019-04-05       Impact factor: 7.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.